HESI FDA BAA study: "Assessing variability and reproducibility of manual and automated patch clamp platforms"
This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.
Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE
Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)
CiPA-specified cardiac ion channels recorded at high throughput
High throughput recordings of cardiac ion channels at physiological temperature
CardioExcyte 96 with integrated liquid handling for cardiac safety screening